You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Formulation of LbL microparticle vaccine in microneedle array for intradermal del

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Practical high resolution microscopy of un-cut, un-embedded lung biopsies

    SBC: Applikate Technologies LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This aim of this Phase I SBIR proposal from Applikate Technology, LLC, is to validate the use of ClearView, a novel approach to performing complete and non-destructive imaging of tissue specimens, for primary pathologyof lung biopsies. Error rates for diagnoses of lung cancer from biopsies may run as high as 15%. Although the root causes of errors are diverse, ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: Calista Therapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Sterculic Acid Analogs to Inhibit Macular Degeneration

    SBC: L2 DIAGNOSTICS, LLC            Topic: NEI

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. System for Multiplex Protein:Protein Interaction Studies Modeled with Antibodies

    SBC: AXIOMX INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): The overarching goal of Phase I is to produce a method that will generate, identify and clone a catalog of protein-protein interactions in a single rapid experiment. In this proposal we will model the technology using antibody-antigen interactions. Recombinant antibody libraries against a proteome could be produced prior to any need, and then desired affinity r ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Development of the VirtualTAVR system for diagnostics and preventative strategies

    SBC: Dura LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Since the first procedure in there has been an explosive growth in transcatheter aortic valve replacement TAVR Up to date more than TAVR had been performed worldwide Despite the increased global experience with TAVR severe adverse events associated with TAVR have been extensively documented including annulus rupture coronary occlusion para ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human Services
  9. Clinical development of 18F PET tracer for imaging VEGF receptors

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative Fast-Track project is clinical development of a novel 18F PET tracer for molecular imaging of receptors for vascular endothelial growth factor (VEGFR). This receptor is the major anti-angiogenic drug target in oncology patients. Critically, VEGFR prevalence decreases when VEGF/VEGFR anti-angiogenic inhibitors work , and increases when these drugs stop worki ...

    SBIR Phase I 2014 Department of Health and Human Services
  10. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human Services
US Flag An Official Website of the United States Government